Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

Lung Cancer

Volumn 54, Issue 3, 2006, Pages 419-422

  Asahina, Hajime ^a   Yamazaki, Koichi ^a   Kinoshita, Ichiro ^a   Yokouchi, Hiroshi ^a   Dosaka Akita, Hirotoshi ^a   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Epidermal growth factor receptor (EGFR); First line therapy; Gefitinib; Mutation; Non small cell lung cancer (NSCLC)

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER GROWTH; CASE REPORT; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOLEUCINE; LEUCINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE; VALINE;

EID: 33750381018     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.005     Document Type: Article

References (19)

1. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
2. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
3. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
4. Kosaka T., Yatabe Y., Mitsudomi T., et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
5. Huang S.F., Liu H.P., Tsai S.F., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
6. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
7. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
8. Tokumo M., Toyooka S., Shimizu N., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 (2005) 1167-1173
9. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
10. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recuccence. J Clin Oncol 23 (2005) 2513-2520
11. Chen Y.R., Fu Y.N., Lin C.H., et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25 (2006) 1205-1215
12. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
13. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
14. Greulich H., Chen T.H., Feng W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PloS Med 2 October 4 (11) (2005) e313
15. Levkowitz G., Waterman H., Ettenberg S.A., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4 (1999) 1029-1040
16. Haglund K., Sigismund S., Polo S., et al. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5 (2003) 461-466
17. Mossesson Y., Shtiegman K., Katz M., et al. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278 (2003) 21323-21326
18. Sugio K., Uramoto H., Ono K., et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 94 (2006) 896-903
19. Wang S.E., Narasanna A., Perez-Torres M., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10 (2006) 25-38